A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

Extranodal Natural Killer/T-cell Lymphoma Clinical Trial

Official title: Prospective, Multicenter Clinical Study of Accurate Stratification and Prognostic Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

Status Not yet recruiting

Clinical Trial Summary

This study is a prospective, multicenter, open-label, single-arm clinical study. This study plans to enroll 72 newly diagnosed ENKTCL patients. The enrollment was completed in 2 years, and the follow-up was terminated in 4 years. To observe the accuracy of circulating free methylated EBV DNA in predicting 2-year PFS rate, 2-year OS rate, and CR rate in newly diagnosed ENKTCL patients; and to clarify the prognostic stratification ability of PINK-cpgE compared with PINK-E

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Extranodal Natural Killer/T-cell Lymphoma
• Lymphoma
• Lymphoma, Extranodal NK-T-Cell
• Lymphoma, T-Cell

• NCT number: NCT05343377
• Study type: Interventional
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: wei xu
• Phone: 025-68306034
• Email: xuwei10000@hotmail.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 1, 2022
• Completion date: June 1, 2028